GW-3965 |
|
(CAS 405911-09-3) |
 |
Description: |
GW3965 is a potent, selective LXR agonist for hLXRα and hLXRβ with EC50 of 190 and 30 nM, respectively.
GW3965 has an EC50 = 125 nM in a cell-free ligand-sensing assay of LXRα and profiles as a full agonist on hLXRα and hLXRβ in cell-based assays with EC50 = 190 nM and 30 nM, respectively. Angiotensin II-mediated increases in blood pressure can be reduced by GW3965 hydrochloride. In HepG2 cells, the EC50 for GW3965 is greater than 4 μM. In an animal study, GW3965 hydrochloride decreased lesion area by 53% 34% in male and female LDLR-/- mice, respectively. GW3965 induced expression of ATP-binding cassettes A1 and G1 in modified low-density lipoprotein-loaded macrophages in vitro as well as in the aortas of hyperlipidemic mice. Additionally, GW3965 hydrochloride increases ABCA1 gene expression and raises circulating HDL levels. GW3965 hydrochloride displays potent antiatherogenic activity in mouse models of atherosclerosis.
|
Product No. |
KT00412 |
Product Name |
GW-3965 |
Synonyms |
|
Formal Name |
|
CAS Number |
405911-09-3 |
Molecular Formula |
C33H31ClF3NO3 |
Formula Weight |
582.05 |
Formulation |
A crystalline solid |
Purity |
98%min |
Stability |
2 years |
Storage |
-20°C |
Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500 |
Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
Price & Availability |
In Stock. Price Negotiated. |
|
Related Products: |
GW3965 hydrochloride
LXR-623
AZD9291
CO-1686 (AVL-301)
EMD 1214063
Erlotinib HCl (OSI-744)
Crizotinib (PF-02341066)
Gefitinib (ZD1839)
Afatinib (BIBW2992)
|
|